NCT06547892 Use of Vasopressin in Patients at High Risk of Acute Kidney Injury Admitted to the ICU
| NCT ID | NCT06547892 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Hospital do Coracao |
| Condition | Critical Illness |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2025-04-10 |
| Primary Completion | 2025-10-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 60 participants in total. It began in 2025-04-10 with a primary completion date of 2025-10-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Renal dysfunction is a frequent complication in patients admitted to intensive care units (ICUs), associated with high morbidity and mortality. Current therapeutic options to prevent this condition are limited and lack robust scientific evidence. This pilot study consists of a multicenter, blinded, randomized clinical trial, unprecedented in the literature to date, aiming to fill this knowledge gap and offer new therapeutic perspectives to improve renal outcomes in critically ill patients admitted to the ICU.
Eligibility Criteria
Inclusion Criteria: * Adult patients (≥18 years old); * Admitted to intensive care units; * Predicted risk of acute kidney injury calculated based on clinical and laboratory data at ICU admission and is considered eligible if the value in the calculator is equal or greater than 5 points; Exclusion Criteria: * Time since admission to the ICU greater than 24 hours; * Use of vasopressors at the time of inclusion; * MAP \>90 mmHg; * Hyponatremia (\<130 mmol/L); * Severe TBI with Glasgow Coma Scale \< 8; * Elective surgeries; * Dialysis chronic kidney disease or acute kidney injury who received renal replacement therapy upon admission or are expected to receive renal replacement therapy within the next 24 hours; * Suspected or confirmed acute mesenteric ischemia; * Prospect of death in less than 24 hours; * Medical team not committed to full investment at the time of inclusion; * Prior inclusion in the study; * Pregnancy.
Contact & Investigator
Matheus Silva
PRINCIPAL INVESTIGATOR
Hospital do Coracao
Frequently Asked Questions
Who can join the NCT06547892 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Critical Illness. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06547892 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06547892 currently recruiting?
Yes, NCT06547892 is actively recruiting participants. Contact the research team at matheus_liguori@hotmail.com for enrollment information.
Where is the NCT06547892 trial being conducted?
This trial is being conducted at São Paulo, Brazil.
Who is sponsoring the NCT06547892 clinical trial?
NCT06547892 is sponsored by Hospital do Coracao. The principal investigator is Matheus Silva at Hospital do Coracao. The trial plans to enroll 60 participants.